Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

Brain Research

Volumn 909, Issue 1-2, 2001, Pages 187-193

  He, Yi ^a   Appel, Stanley ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Microglia; Minocycline; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

MINOCYCLINE; OXIDOPAMINE; PROTEIN TYROSINE KINASE;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOCOMPETENT CELL; MALE; MICROGLIA; MOUSE; MOUSE STRAIN; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL DEATH; DISEASE MODELS, ANIMAL; GLIOSIS; IMMUNOHISTOCHEMISTRY; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED ICR; MICROGLIA; MINOCYCLINE; NEOSTRIATUM; NERVE DEGENERATION; OXIDOPAMINE; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 0035800589     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02681-6     Document Type: Article

References (38)

1. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions
2. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines
3. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
4. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen
5. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
6. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins
7. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model
8. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis
9. Microglia: Intrinsic immunoeffector cell of the brain
10. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells
11. Microglia responses in the CNS following sciatic nerve transection in C57BL/Wids and BALB/c mice
12. Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesiong
13. Region-specific activation of microglial cells in the rat septal complex following fimbria-fornix transection
14. Cytokines and the nervous system. I: Expression and recognition
15. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease
16. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: Evidence for cell death in the substantia nigra
17. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue
18. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
19. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse
20. Microglia: A sensor for pathological events in the CNS
21. Evidence of active nerve cell degeneration in the substantia nigra of humans years after1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
22. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
23. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide
24. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation
25. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats
26. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
27. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
28. Cytokines and neuropathology
29. Neuronal control of the immune response in the central nervous system: Linking brain immunity to neurodegeneration
30. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with anunbiased stereological method
31. Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomized mouse facial motor nucleus and aggregate around sites of neuronal degeneration
32. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus
33. Expression of Ia antigen on perivascular and microglia cells after sublethal and lethal motoneuron injury
34. Treatment of the adult retina with microglia suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regenration in vivo and in vitro
35. Herpes simplex type I infection of the CNS induces major histocompatibility complex antigen expression on rat microglia
36. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
37. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
38. Neuron-microglia interaction in vitro